Publication

An Economic Evaluation of Sacubitril/Valsartan for Heart Failure Patients in the Netherlands

van der Pol, S., Degener, F., Postma, M. J. & Vemer, P., Mar-2017, In : Value in Health. 20, 3, p. 388-396 9 p.

Research output: Contribution to journalArticleAcademicpeer-review

Copy link to clipboard

Documents

  • An Economic Evaluation of Sacubitril/Valsartan for Heart Failure Patients in the Netherlands

    Final publisher's version, 1.33 MB, PDF document

DOI

Background: In September 2014, the PARADIGM-HF trial showed the heart failure drug combination sacubitril/valsartan to be superior to enalapril for patients with a reduced ejection fraction. Objectives: To determine the incremental cost-effectiveness of sacubitril/valsartan compared with enalapril in the Netherlands using the clinical data from the PARADIGM-HF trial. Methods: To compare sacubitril/valsartan and enalapril in a cost-effectiveness study, a Markov model was developed using the effectiveness data from the PARADIGM-HF trial. A health care payer's perspective was applied in the economic evaluation. The developed model was used to evaluate the costeffectiveness for sacubitril/valsartan at different per diem prices. Results: The base-case analysis showed that sacubitril/valsartan can be cost-effective at maximum daily costs of (sic)5.50 and (sic)14.14 considering willingness-to-pay thresholds of (sic)20,000 and (sic)50,000 per quality-adjusted life-year (QALY), respectively. Sensitivity analysis demonstrated the robustness of the model, identifying only the price of sacubitril/valsartan and the mortality within the sacubitril/valsartan group as significant drivers of the cost-effectiveness ratio. Sacubitril/valsartan was cost-effective at a willingness-to-pay threshold of (sic)20,000 per QALY ((sic)50,000 per QALY) in more than 80% of the replications with certainty at the price point of(sic) ((sic)10). Conclusions: Sacubitril/valsartan can be considered a cost-effective treatment at a daily price of 5.25. Unless priced lower than enalapril (

Original languageEnglish
Pages (from-to)388-396
Number of pages9
JournalValue in Health
Volume20
Issue number3
Publication statusPublished - Mar-2017

    Keywords

  • economic evaluation, heart failure, valsartan/sacubitril, INTENSIVE-CARE UNITS, NEPRILYSIN INHIBITION, COST-EFFECTIVENESS, EJECTION FRACTION, ENALAPRIL, LCZ696, HOSPITALIZATION, POPULATION, PREVALENCE, IVABRADINE
Related Publications
  1. Cost-Effectiveness of Sacubitril/Valsartan in Germany: An Application of the Efficiency Frontier

    van der Pol, S., de Jong, L. A., Vemer, P., Jansen, D. E. M. C. & Postma, M., Oct-2019, In : Value in Health. 22, 10, p. 1119-1127 9 p.

    Research output: Contribution to journalArticleAcademicpeer-review

View all (1) »

Related Activities
  1. EHMA 2018 ANNUAL CONFERENCE

    Simon Pol, van der (Speaker), Maarten Postma (Contributor)
    21-Jun-2018

    Activity: Participating in or organising an eventParticipation in conferenceAcademic

View all (1) »

ID: 40504522